Enhertu combo wins FDA approval for first-line use in metastatic breast cancernews2025-12-15T20:39:58+00:00December 15th, 2025|Endpoints News|
FDA speeds up review of J&J’s multiple myeloma combo treatment following positive datanews2025-12-15T19:25:21+00:00December 15th, 2025|Endpoints News|
With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labelsnews2025-12-15T19:02:49+00:00December 15th, 2025|Endpoints News|
Gilead posts second Phase 3 win for new HIV-fighting drug regimennews2025-12-15T17:47:26+00:00December 15th, 2025|Endpoints News|
Aviceda’s geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?news2025-12-15T16:23:32+00:00December 15th, 2025|Endpoints News|
Palvella unwraps Phase 2 data for rapamycin gel in rare skin diseasenews2025-12-15T16:20:31+00:00December 15th, 2025|Endpoints News|
InnoCare says Zenas-partnered drug succeeds in China study in form of lupusnews2025-12-15T16:15:00+00:00December 15th, 2025|Endpoints News|
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trialnews2025-12-15T16:10:23+00:00December 15th, 2025|Endpoints News|
Areteia Therapeutics to wind down after terminating Phase 3 asthma studiesnews2025-12-15T15:56:19+00:00December 15th, 2025|Endpoints News|
Immunome’s rare tumor drug passes Phase 3 test, could challenge Merck KGaAnews2025-12-15T15:34:08+00:00December 15th, 2025|Endpoints News|
